By Eric Sagonowsky
For more than a decade, Merck has been defending itself against claims its osteoporosis drug Fosamax caused patients to suffer “atypical femoral fractures," even taking its fight to the Supreme Court, where it eked out a win. Now, after that SCOTUS fight, the company has prevailed against 500 Fosamax lawsuits.
read more
By Heather Landi
Cityblock Health, a healthcare provider focused on marginalized populations with complex needs, has tapped Toyin Ajayi, M.D. as its new chief executive officer.
read more
By Max Bayer
Roivant Social Ventures is partnering with San Diego-based drug discovery center Sanford Burnham Prebys to launch a new Ph.D. program designed to bolster diversity in biopharma. The program aims to provide hands-on training in all aspects of drug development, from discovery to clinical trials.
read more
By Andrea Park
After spending much of 2021 growing its footprint beyond the U.S. by acquiring a handful of diagnostic developers scattered across Europe and expanding its women’s health-focused offerings throughout the continent, Hologic is deepening its ties there.
read more
By Angus Liu
Novartis has pushed its second radioligand therapy over the FDA finish line. Building on the experience with Lutathera, the company hopes the new prostate cancer drug could reach over $2 billion in peak sales.
read more
By Ben Adams
It’s March, so it’s time for some #FierceMadness. We’re looking for the best of the best in drug names—and this round we saw wins for Bristol Myers, BioMarin, Gilead, Eli Lilly and more, as AstraZeneca and Takeda drugs dropped out. Now it's time to get voting for your Elite 8.
read more
By Anastassia Gliadkovskaya
Most physicians had at least some patients affected by social factors but felt inadequately equipped to address them.
read more
By Annalee Armstrong
Pfizer’s respiratory syncytial virus (RSV) program is piling on the wins. After gaining a breakthrough tag for its maternal vax program earlier this month, the New York pharma added the same designation for prevention of RSV in older adults.
read more
By Zoey Becker
The good news for Sun Pharma is that it's closed the books on one more legal problem it inherited from its Ranbaxy Laboratories buyout eight years ago. The bad: It's going to cost the generics maker $485 million.
read more
By Heather Landi
As COTA looks to expand its oncology real-world data and analytics expertise in healthcare and life sciences, the company tapped pharma veteran Miruna Sasu, Ph.D., as its new CEO and president.
read more
By Annalee Armstrong
Homology Medicines is adding an immunosuppressive regimen to a phase 1/2 trial for its phenylketonuria gene therapy, hoping to quell FDA concerns that triggered a clinical hold in February.
read more
By Conor Hale
Paige’s AI program aims to increase the chances of spotting potential tumors of any size, including micrometastases that might otherwise go unnoticed.
read more
By Kevin Dunleavy
The roller coaster ride for AstraZeneca’s blockbuster cancer drug Imfinzi has taken a sudden dip, with a swing and a miss in cervical cancer. The company said its phase 3 trial of Imfinzi combined with chemoradiotherapy failed to show that it could slow disease progression and extend the chance for survival better than chemoradiotherapy alone.
read more
By Gareth Macdonald
Aduhelm maker Biogen has set up a data network to track how neurological disease medicines perform in the real world after clinical trials.
read more
